alexa TMEM4 is Highly Expressed in Plasma Cell Neoplasms and

Immunological Disorders & Immunotherapy
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

TMEM4 is Highly Expressed in Plasma Cell Neoplasms and Associated with B Lymphocyte Differentiation

Chen-Feng Qi1*, Shao Xiang1,2, Guifang Ouyang3, Xing-pei Hao1, Min Sun Shin1, Alexander L Kovalchuk1, Peng Liang4, Huabao Xiong4,Herbert C Morse III1, Zhengping Zhuang5, Jeff X Zhou3 and Susan K Pierce1

1Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, USA

2Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, USA

3Ningbo University School of Medicine, Ningbo, China

4Immunology Institute, Mount Sinai School of Medicine, New York, USA

5Molecular Pathogenesis Unit, Surgical Neurology Branch, National Institutes of Cancer, National Institutes of Health, Bethesda, USA

*Corresponding Author:
Chen-Feng Qi
Laboratory of Immunogenetics
National Institute of Allergy and Infectious Diseases
National Institutes of Health, 5640 Fishers Lane
Rockville, MD, 20852, USA
Tel: (301)761-3986
Fax: (301)402-0077
E-mail: [email protected]

Received date: January 14, 2016 Accepted date: January 29, 2016 Published date: February 01,2016

Citation: Qi C, Xiang S, Ouyang G, Hao X, Shin MS, et al. (2016) TMEM4 is Highly Expressed in Plasma Cell Neoplasms and Associated with B Lymphocyte Differentiation. Immunol Disord Immunother 1:102.

Copyright: © 2016 Qi C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Aiming to identify biomarkers for plasma cell neoplasms, we analyzed gene expression profile and proteomic characteristics of mouse models of plasmacytomas along with other types of B-cell neoplasms. We found that transmembrane protein 4 (Tmem4) was highly expressed in plasmacytomas in comparison with early-stage B-cell neoplasms. The serum levels of Tmem4 were also significantly greater in mice with plasmacytoma comparing to those with early-stage B-cell neoplasms (P<0.01). Mechanistically, increased Tmem4 expression in B cells led to increased levels of IL-10, a cytokine that promotes the growth of malignant plasma cells and participates in the terminal differentiation of B cells into plasma cells. In addition, over-expression of Tmem4 promoted B cell terminal differentiation as evidenced by the increase in expression of XBP1, CD38, and CD138. Furthermore, we found that TMEM4 was highly expressed in plasma cells of multiple myeloma patients. These findings suggested that Tmem4 plays an important role in plasma cell differentiation and has a potential to serve as a biomarker for plasma cell neoplasms.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version